m-Chloroperbenzoic acid → 1-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-2-methyl-5-oxido-1H-imidazo[4,5-c][1,5]naphthyridine
Reaktionsgleichung
[F:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[CH:12]=[C:11]([CH2:13][N:14]3[C:26]4[C:25]5[N:24]=[CH:23][CH:22]=[CH:21][C:20]=5[N:19]=[CH:18][C:17]=4[N:16]=[C:15]3[CH3:27])[O:10][N:9]=2)=[CH:4][CH:3]=1.C1C=C(Cl)C=C(C(OO)=[O:36])C=1>>[F:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[CH:12]=[C:11]([CH2:13][N:14]3[C:26]4[C:25]5[N:24]=[CH:23][CH:22]=[CH:21][C:20]=5[N+:19]([O-:36])=[CH:18][C:17]=4[N:16]=[C:15]3[CH3:27])[O:10][N:9]=2)=[CH:4][CH:3]=1Komponenten
3
Versuchsvorschrift
The method described in Part E of Example 12 was used to treat 1-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridine (1.15 g, 3.20 mmol) with mCPBA (0.94 g of 75% pure material followed by 0.25 g) to provide 1-{[3-(4-fluorophenyl)isoxazol-5-yl]methyl}-2-methyl-5-oxido-1H-imidazo[4,5-c][1,5]naphthyridine as a dark yellow solid.